Premium
Pharmacologic studies of indoramin in man
Author(s) -
Royds R. B.,
Coltart D. J.,
Lockhart J. D. F.
Publication year - 1972
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1972133380
Subject(s) - placebo , blood pressure , medicine , supine position , anesthesia , pharmacology , flicker fusion threshold , propranolol , alternative medicine , pathology , electrical engineering , flicker , engineering
The effects of indoramin, a new hypotensive drug with competitive α‐adrenergic receptor blocking properties, were studied in a double‐blind investigation in healthy human subjects. Indoramin (20 mg.) orally produced a significant fall in blood pressure at high exercise loads when compared with placebo. Indoramin (20 and 40 mg.) reduced erect blood pressures during a period of 6 hours when compared with placebo in another double‐blind study. Histamine skin wheals were also reduced in a dose‐related manner but no effect on critical flicker frequency was demonstrated. The pressor response to intravenous norepinephrine showed a parallel time‐related shift to the right after the intravenous administration of 20 mg. of indoramin. The effect of intravenous indoramin (10 mg.) on myocardial funcion was studied with noninvasive techniques. No effect was demonstrated on systolic time intervals, cardiac output, or eiection fraction. Indoramin (20 mg.) given orally twice daily for 2 weeks reduced erect and supine blood pressures without evidence of drug accumulation. No drug‐related effects on biochemical or hematologic values were detected.